News und Analysen
EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and advances Joint Pharmaceutical Technology Development
Vancouver, B.C., November 13, 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced
EnWave unterzeichnet Anlagenkaufvertrag mit GEA Lyophil GmbH und treibt gemeinsame Entwicklung der pharmazeutischen Technologie voran
Vancouver, B.C., 13. November 2020
Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab
IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the
Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the
Relay Medical & Fio Announces Over $500,000 CAD in Contracts for Fionet Mobile COVID-19 Testing & Tracking Platform; Provides Operational Update
- Relay & Fio joint venture, Fio Rapid Response Group, announce over $500,000 CAD in initial contracts
- Fionet is a first-of-its-kind mobile testing & tracking platform
Relay Medical & Fio meldet Verträge im Wert von über $500.000 CAD für Fionet Mobile COVID-19 Test- und Nachverfolgungsplattform und stellt operatives Update zur Verfügung
- Relay & Fio Joint Venture, Fio Rapid Response Group, kündigen über $500.000 CAD in ersten Verträgen an
- Fionet ist die erste mobile Test- und Nachverfolgungsplattform
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies
EnWave unterzeichnet erste kommerzielle Lizenz zur Zahlung von Lizenzgebührenür die Verarbeitung von Cannabis in den Vereinigten Staaten
Vancouver, B.C., 12. November 2020
Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
EnWave Signs First Commercial Royalty-Bearing License for Cannabis Processing in the United States
Vancouver, B.C., November 12 , 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced
IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases
Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent
IMV Strengthens Leadership Team with Appointment of Andrew Hall as Chief Business Officer
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced the
Antibe Therapeutics Receives Final Approval to Graduate to the Toronto Stock Exchange
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced
Relay Medical Subsidiary Signs Binding LOI for Rights to COVID-19 Rapid Antigen and Antibody Tests
November 9, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, announces that it has entered into a binding
Tochtergesellschaft von Relay Medical unterzeichnet verbindliche Absichtserklärung zum Erwerb der Rechte an COVID-19-Antigen- und Antikörper-Schnelltests
9. November 2020 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), ein Entwickler von Innovationen in der Medizintechnik, gibt bekannt, dass das
IMV to Participate in Two Upcoming Investor Conferences
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company, today announced data from an integrated analysis of the AURA-LV and
IMV’s T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck’s Keytruda® in PD-L1 Positive Patients with r/r DLBCL
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the Company’s T cell therapy demonstrates an 86%
Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV’s T Cell Therapy in Combination With Merck’s Keytruda® in Patients With r/r DLBCL to Be Presented at The American Society of Hematology Annual Meeting
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that
Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced topline data from the Phase 2/3 AUDREY™ clinical
Antibe Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to
IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
NeutriSci Provides Update on Product Launch in Japan
Vancouver, British Columbia – October 28, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
NeutriSci informiert über die Produkteinführung in Japan
Vancouver, British Columbia – 28. Oktober 2020 – NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) – ein innovatives
Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications